The CETP inhibitor was initially developed by Dezima Pharma, which was acquired by Amgen, but was dropped by its new owner in 2017 around the time Merck abandoned anacetrapib. Amgen licensed the ...

Obicetrapib is a selective inhibitor of cholesteryl ester transfer protein (CETP). By blocking CETP, these inhibitors work to increase high-density lipoprotein (HDL) cholesterol and lower ...

The motivation to go ahead in this directon will largely depend on the outcomes of the ongoing clinical end point trials on fenofibrate, nicotinic acid and CETP inhibitors. Expert Rev Cardiovasc Ther.

Low HDL-cholesterol levels are associated, therefore, with the defective functionality of small HDL particles of abnormal structure and ... "LDL oxidation", "CETP inhibitor" and "torcetrapib".

On 18 November, at the American Heart Association (AHA) 2024 Annual Scientific Sessions in Chicago, Illinois, US, during a late-breaking session on the topic of “New Targets and New Treatments ...